ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
(Address of principal executive offices) |
(Zip Code) |
Title of Each Class: |
Trading Symbol(s) |
Name of Each Exchange on Which Registered: | ||
one-half of one redeemable warrant |
||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ | Smaller reporting company | |||||
Emerging growth company |
• | our ability to complete our initial business combination; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements; |
• | our potential ability to obtain additional financing to complete our initial business combination; |
• | the ability of our officers and directors to generate a number of potential acquisition opportunities; |
• | our pool of prospective target businesses; |
• | the ability of our officers and directors to generate a number of potential acquisition opportunities; |
• | our public securities’ potential liquidity and trading; |
• | the lack of a market for our securities; |
• | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; or |
• | our financial performance. |
• | “amended and restated memorandum and articles of association” are to the amended and restated memorandum and articles of association that the company adopted prior to the consummation of our initial public offering; |
• | “board of directors,” “board” or “directors” are to the board of directors of the Company; |
• | “BDO” are to BDO USA, LLP, our independent registered public accounting firm; |
• | “Class A ordinary shares” are to the Class A ordinary shares of the Company, par value $0.0001 per share; |
• | “Class B ordinary shares” are to the shares of Class B ordinary shares of the Company, par value $0.0001 per share; |
• | “Companies Act” are to the Companies Act (Revised) of the Cayman Islands as the same may be amended from time to time; |
• | “Continental” are to Continental Stock Transfer & Trust Company, trustee of our trust account (as defined below) and warrant agent of our public warrants (as defined below); |
• | “DWAC System” are to the Depository Trust Company’s Deposit/Withdrawal At Custodian System; |
• | “Exchange Act” are to the Securities Exchange Act of 1934, as amended; |
• | “founder shares” are to our Class B ordinary shares initially issued to our sponsor in a private placement prior to our initial public offering and including those subsequently transferred to our officers and directors to the extent they hold such shares, and the Class A ordinary shares that will be issued upon the automatic conversion of the Class B ordinary shares at the time of our initial business combination or earlier at the option of the holders thereof (for the avoidance of doubt, such Class A ordinary shares will not be “public shares” (as defined below)); |
• | “GAAP” are to the accounting principles generally accepted in the United States of America; |
• | “IFRS” are to the International Financial Reporting Standards, as issued by the International Accounting Standards Board; |
• | “initial business combination” are to a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses; |
• | “initial public offering” are to the initial public offering that was consummated by the Company on December 13, 2021; |
• | “initial shareholders” are to all of our shareholders immediately prior to the date of our initial public offering, including our sponsor and all of our officers and directors to the extent they hold such shares; |
• | “Investment Company Act” are to the Investment Company Act of 1940, as amended; |
• | “JOBS Act” are to the Jumpstart Our Business Startups Act of 2012; |
• | “management” or our “management team” are to our executive officers and directors; |
• | “NYSE” are to the New York Stock Exchange; |
• | “ordinary shares” are to the Class A ordinary shares and the Class B ordinary shares; |
• | “PCAOB” are to the Public Company Accounting Oversight Board (United States); |
• | “private placement warrants” are to the warrants that were issued to our sponsor in a private placement simultaneously with the closing of our initial public offering and the warrants that will be issued upon conversion of working capital loans, if any; |
• | “public shares” are to our Class A ordinary shares sold as part of the units (as defined below) in our initial public offering (whether they were purchased in our initial public offering or thereafter in the open market); |
• | “public shareholders” are to the holders of our public shares, including our initial shareholders to the extent our sponsor and/or members of our management team purchase public shares, provided that our initial shareholders’ status as a “public shareholder” only exists with respect to such public shares; |
• | “public warrants” are to the warrants sold as part of the units in our initial public offering (whether they were purchased in our initial public offering or thereafter in the open market); |
• | “Registration Statement” are to the Registration Statement on Form S-1 initially filed with the SEC on November 3, 2021 (File No. 333-260713), as amended; |
• | “Report” are to this Annual Report on Form 10-K for the fiscal year ended December 31, 2021; |
• | “Sarbanes-Oxley Act” are to the Sarbanes-Oxley Act of 2002; |
• | “SEC” are to the U.S. Securities and Exchange Commission; |
• | “Securities Act” are to the Securities Act of 1933, as amended; |
• | “sponsor” are to IWH Sponsor LP, a Delaware limited partnership; |
• | “trust account” are to the U.S.-based trust account in which an amount of $117,300,000 ($10.20 per unit) from the net proceeds of the sale of the units in the initial public offering and the private placement warrants was placed following the closing of the initial public offering; |
• | “units” are to the units sold in our initial public offering, which consist of one public share and one-half of one public warrant; |
• | “warrants” are to our redeemable warrants, which includes the public warrants as well as the private placement warrants; and |
• | “we,” “us,” “Company” or “our Company” are to Integrated Wellness Acquisition Corp, a Cayman Islands exempted company. |
• | Strong consumer brand awareness, engagement and affinity; |
• | Category-leader or disruptor in the highest-growth segments of the industry; |
• | Clear and substantiated impact on consumer health and wellness outcomes; |
• | Tech-enabled or the opportunity to bring technology into the consumer health experience; |
• | Strong growth with further growth opportunities either via geographic, product or channel diversification; and |
• | Strong economics or high potential for improvement. |
• | Aligned with growing, recession-resistant target sectors: |
• | A recognized and effective brand: |
• | A category leader or disruptor with a clear path to get there: |
• | High growth with favorable profitability characteristics: |
• | Digitally-enabled with scalable technology: |
• | Delivering sustainable consumer outcomes: |
• | Poised to benefit from being a public company: |
• | Led by a proven and experienced team |
• | Available at an attractive valuation: |
• | A platform for growth add-ons. |
• | Upside opportunities |
• | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industries in which we operate after our initial business combination; and |
• | cause us to depend on the marketing and sale of a single product or limited number of products or services. |
• | We issue ordinary shares that will be equal to or in excess of 20% of the number of our ordinary shares then-outstanding (other than in a public offering); |
• | Any of our directors, officers or substantial stockholders (as defined by the NYSE rules) has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of shares of our ordinary shares could result in an increase in outstanding ordinary shares or voting power of 5% or more; or |
• | The issuance or potential issuance of ordinary shares will result in our undergoing a change of control. |
• | the timing of the transaction, including in the event we determine shareholder approval would require additional time and there is either not enough time to seek shareholder approval or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the company; |
• | the expected cost of holding a shareholder vote; |
• | the risk that the shareholders would fail to approve the proposed business combination; |
• | other time and budget constraints of the company; and |
• | additional legal complexities of a proposed business combination that would be time-consuming and burdensome to present to shareholders. |
• | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and |
• | file proxy materials with the SEC. |
• | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers; and |
• | file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
Item 1A. |
Risk Factors. |
• | we are a blank check company with no revenue or basis to evaluate our ability to select a suitable business target; |
• | we may not be able to select an appropriate target business or businesses and complete our initial business combination in the prescribed time frame; |
• | our expectations around the performance of a prospective target business or businesses may not be realized; |
• | we may not be successful in retaining or recruiting required officers, key employees or directors following our initial business combination; |
• | our officers and directors may have difficulties allocating their time between the Company and other businesses and may potentially have conflicts of interest with our business or in approving our initial business combination; |
• | we may not be able to obtain additional financing to complete our initial business combination or reduce the number of shareholders requesting redemption; |
• | we may issue our shares to investors in connection with our initial business combination at a price that is less than the prevailing market price of our shares at that time; |
• | you may not be given the opportunity to choose the initial business target or to vote on the initial business combination; |
• | trust account funds may not be protected against third party claims or bankruptcy; |
• | an active market for our public securities’ may not develop and you will have limited liquidity and trading; |
• | the availability to us of funds from interest income on the trust account balance may be insufficient to operate our business prior to the business combination; |
• | our financial performance following a business combination with an entity may be negatively affected by their lack an established record of revenue, cash flows and experienced management; |
• | there may be more competition to find an attractive target for an initial business combination, which could increase the costs associated with completing our initial business combination and may result in our inability to find a suitable target; |
• | changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination; |
• | we may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability; |
• | we may engage one or more of our underwriters or one of their respective affiliates to provide additional services to us after the initial public offering, which may include acting as a financial advisor in connection with an initial business combination or as placement agent in connection with a related financing transaction. Our underwriters are entitled to receive deferred underwriting commissions that will be released from the trust account only upon a completion of an initial business combination. These financial incentives may cause them to have potential conflicts of interest in rendering any such additional services to us after the initial public offering, including, for example, in connection with the sourcing and consummation of an initial business combination; |
• | we may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all; |
• | since our initial stockholders will lose their entire investment in us if our initial business combination is not completed (other than with respect to any public shares they may acquire during or after our initial public offering), and because our sponsor, officers and directors may profit substantially even under circumstances in which our public stockholders would experience losses in connection with their investment, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination; |
• | changes in laws or regulations or how such laws or regulations are interpreted or applied, or a failure to comply with any laws or regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations; |
• | the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the trading price of our ordinary shares at such time is substantially less than $10.00 per share; and |
• | resources could be wasted in researching acquisitions that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we have not completed our initial business combination within the required time period, our public stockholders may receive only approximately $10.20 per share, or less than such amount in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless. |
Item 1B. |
Unresolved Staff Comments. |
Item 2. |
Properties. |
Item 3. |
Legal Proceedings. |
Item 4. |
Mine Safety Disclosures. |
Item 5. |
Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities. |
• | may significantly dilute the equity interest of investors in our initial public offering, which dilution would further increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one |
• | may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
• | could cause a change in control if a substantial number of our Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
• | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; |
• | may adversely affect prevailing market prices for our units, Class A ordinary shares and/or warrants; and |
• | may not result in adjustment to the exercise price of our warrants. |
• | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
• | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
• | our inability to pay dividends on our Class A ordinary shares; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
Item 7A. |
Quantitative and Qualitative Disclosures about Market Risk. |
Item 8. |
Financial Statements and Supplementary Data. |
Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. |
Item 9A. |
Controls and Procedures. |
Item 9B. |
Other Information. |
Item 9C. |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. |
Name |
Age |
Title | ||
Steven Schapera | 62 | Chief Executive Officer and Director | ||
Antonio Varano Della Vergiliana | 65 | Chairman of the Board | ||
James MacPherson | 53 | Chief Financial Officer and Director | ||
Robert Quandt | 43 | Chief Operating Officer and Director | ||
Gael Forterre | 41 | Director | ||
Scott Powell | 49 | Director | ||
Hadrien Forterre | 33 | Director |
• | meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; |
• | monitoring the independence of the independent registered public accounting firm; |
• | verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; |
• | inquiring and discussing with management our compliance with applicable laws and regulations; |
• | pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; |
• | appointing or replacing the independent registered public accounting firm; |
• | determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; |
• | establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; |
• | monitoring compliance on a quarterly basis with the terms of our initial public offering and, if any noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of our initial public offering; and |
• | reviewing and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors abstaining from such review and approval. |
• | identifying, screening and reviewing individuals qualified to serve as directors and recommending to the board of directors candidates for nomination for election at a general annual meeting or to fill vacancies on the board of directors; |
• | developing, recommending to the board of directors and overseeing implementation of our corporate governance guidelines; |
• | coordinating and overseeing the annual self-evaluation of the board of directors, its committees, individual directors and management in the governance of the company; and |
• | reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary. |
• | should have demonstrated notable or significant achievements in business, education or public service; |
• | should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and |
• | should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders. |
• | reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; |
• | reviewing and approving the compensation of all of our other executive officers; |
• | reviewing our executive compensation policies and plans; |
• | implementing and administering our incentive compensation equity-based remuneration plans; |
• | assisting management in complying with our proxy statement and annual report disclosure requirements; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees; |
• | producing a report on executive compensation to be included in our annual proxy statement; and |
• | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
● | each person known by us to be the beneficial owner of more than 5% of our outstanding ordinary shares; |
● | each of our executive officers and directors that beneficially owns our ordinary shares; and |
● | all our executive officers and directors as a group. |
Class A Ordinary Shares |
Class B Ordinary Shares |
Approximate |
||||||||||||||||||
Name and Address of Beneficial Owner (1) |
Number of Shares Beneficially Owned |
Approximate Percentage of Class |
Number of Shares Beneficially Owned (2) |
Approximate Percentage of Class |
Percentage of Outstanding Ordinary Shares |
|||||||||||||||
IWH Sponsor LP |
— | — | 2,875,000 | 100 | % | 20 | % | |||||||||||||
Steven Schapera |
— | — | — | — | — | |||||||||||||||
Antonio Varano Della Vergiliana |
— | — | 2,875,000 | 100 | % | 20 | % | |||||||||||||
James MacPherson |
— | — | 2,875,000 | 100 | % | 20 | % | |||||||||||||
Robert Quandt |
— | — | — | — | — | |||||||||||||||
Gael Forterre |
— | — | — | — | — | |||||||||||||||
Scott Powell |
— | — | — | — | — | |||||||||||||||
Hadrien Forterre |
— | — | 2,875,000 | 100 | % | 20 | % | |||||||||||||
All officers and directors as a group (7 individuals) |
— | — | 2,875,000 | 100 | % | 20 | % | |||||||||||||
Other 5% Shareholders |
||||||||||||||||||||
Saba Capital Management, L.P. (3) |
625,000 | 5.43 | % | — | — | 4.35 | % |
(1) | Unless otherwise noted, the business address of each of the following entities or individuals is c/o Integrated Wellness Acquisition Corp, 148 N Main Street, Florida, NY 10921. |
(2) | IWH Sponsor LP, our sponsor, is the record holder of 2,875,000 Class B ordinary shares. IWH Sponsor GP LLC is the general partner of our sponsor. Hadrien Forterre, Antonio Varano Della Vergiliana and Arcturus Holdings, LLC are the managing members of IWH Sponsor GP LLC. James MacPherson is the managing member of Arcturus Holdings, LLC. By virtue of these relationships, each of these entities and individuals may be deemed to share beneficial ownership of the securities held of record by our sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. |
(3) | According to a Schedule 13G filed on December 17, 2021, Saba Capital Management, L.P., a Delaware limited partnership, Saba Capital Management GP, LLC, a Delaware limited liability company, and Mr. Boaz R. Weinstein, a citizen of the United States (together, the “Reporting Persons”) hold 625,000 of our Class A ordinary shares. The business address for each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174. |
(1) |
Financial Statements |
(BDO USA, LLP; Charlotte, NC; PCAOB # |
F-2 |
|||
F-3 |
||||
F-4 |
||||
Statement of Changes in Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit | F-5 |
|||
F-6 |
||||
F-7 to F-20 |
(2) |
Financial Statement Schedules |
(3) |
Exhibits |
(BDO USA, LLP; Charlotte, NC; PCAOB #243) |
F-2 |
|||
Financial Statements: |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 to F-20 |
December 31, 2021 |
||||
ASSETS |
||||
Current assets: |
||||
Cash |
$ | |||
Prepaid expenses |
||||
|
|
|||
Total Current Assets |
||||
|
|
|||
Non-current assets |
||||
Cash and Marketable securities held in Trust |
||||
|
|
|||
Total Non-current Assets |
||||
|
|
|||
Total Assets |
$ | |||
|
|
|||
LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT |
||||
Current liabilities |
||||
Accrued expenses |
$ | |||
Accounts Payable |
||||
Accrued offering costs |
||||
|
|
|||
Total Current Liabilities |
||||
|
|
|||
Non-Current liabilities |
||||
Deferred underwriter fee |
||||
|
|
|||
Total Non-current Liabilities |
||||
|
|
|||
Total Liabilities |
||||
|
|
|||
Commitments and contingencies (Note 7) |
||||
Class A ordinary shares subject to possible redemption; $ |
||||
Shareholders’ Deficit |
||||
Preference shares, $ |
||||
Class A ordinary shares, $ |
||||
Class B ordinary shares, $ |
||||
Additional paid-in capital |
||||
Accumulated deficit |
( |
) | ||
|
|
|||
Total Shareholders’ Deficit |
( |
) | ||
|
|
|||
TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT |
$ | |||
|
|
Formation and operating costs |
$ | |||
Accounting and legal expense |
||||
Insurance expense |
||||
Advertising and marketing expense |
||||
|
|
|||
Loss from operations |
( |
) | ||
|
|
|||
Other income (expense): |
||||
Interest earned on marketable securities held in Trust Account |
||||
Unrealized gain on marketable securities held in Trust Account |
||||
|
|
|||
Other income, net |
||||
|
|
|||
Net Loss |
$ |
( |
) | |
|
|
|||
Basic and diluted weighted average shares outstanding, Class A ordinary shares |
||||
Basic and diluted net income per share, Class A ordinary shares |
$ |
|||
|
|
|||
Basic and diluted weighted average shares outstanding, Class B ordinary shares |
||||
Basic and diluted net loss per share, non-redeemable Class B ordinary shares |
$ |
( |
) | |
|
|
Class A Ordinary shares Subject to Possible Redemption |
Class B Ordinary shares |
Additional Paid-In Capital |
Accumulated deficit |
Total shareholders’ deficit |
||||||||||||||||||||||||||||
No. of shares |
Amount |
No. of shares |
Amount |
|||||||||||||||||||||||||||||
Balance - July 7, 2021 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||||||||||||||
Issuance of Class B ordinary shares to Sponsor |
— | — | — | |||||||||||||||||||||||||||||
Issuance of Class A ordinary shares |
— | — | — | — | — | |||||||||||||||||||||||||||
Proceeds allocated to public warrants |
— | — | — | — | — | |||||||||||||||||||||||||||
Issuance of Private Placement Warrants |
— | — | — | — | — | |||||||||||||||||||||||||||
Accretion of Class A ordinary shares to redemption value |
— | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Balance - December 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flow from Operating Activities: |
||||
Net loss |
$ | ( |
||
|
|
|||
Adjustments to reconcile net loss to net cash provided by operating activities |
||||
Interest earned on marketable securities held in Trust Account |
( |
) | ||
Unrealized loss on marketable securities held in Trust Account |
( |
) | ||
Changes in operating assets and liabilities |
||||
Prepaid expense s |
|
|
( |
) |
Accounts payable and accrued expenses |
||||
|
|
|||
Net cash used in operating activities |
( |
) | ||
|
|
|||
Cash Flow from Investing Activities: |
||||
Investment of cash and marketable securities in trust account |
( |
) | ||
|
|
|||
Net cash used in investing activities |
( |
) | ||
|
|
|||
Cash Flow from Financing Activities: |
||||
Proceeds from issuance of Class A ordinary shares |
||||
Payment of underwriting fee |
( |
) | ||
Proceeds from issuance of Private Placement Warrants |
||||
Repayment of promissory note - related party |
( |
) | ||
Payment of deferred offering costs |
( |
) | ||
|
|
|||
Net cash provided by financing activities |
||||
|
|
|||
Net Change in Cash |
||||
Cash—Beginning of the period |
||||
|
|
|||
Cash—End of the period |
$ |
|||
|
|
|||
Non-Cash Investing and Financing Activities: |
||||
Accretion of Class A ordinary shares subject to possible redemption |
$ | |||
Deferred underwriters fee liability |
$ | |||
Deferred offering costs included in accrued offering costs |
$ | |||
Deferred offering costs paid by sponsor through promissory note |
$ |
• | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as calculations derived from valuation techniques in which one or more significant inputs or significant value drivers are observable. |
Gross proceeds from initial public offering |
$ | |||
Less: |
||||
Proceeds allocated to public warrants |
( |
) | ||
Offering costs allocated to Class A ordinary shares subject to possible redemption |
( |
) | ||
Plus: |
||||
Re-measurement on Class A ordinary shares subject to possible redemption amount |
||||
Class A ordinary shares subject to possible redemption, December 31, 2021 |
$ |
|||
For the period from July 7, 2021 (inception) December 31, 2021 |
||||
Net Loss |
( |
) | ||
Accretion of temporary equity to redemption value |
( |
) | ||
Net loss including accretion of temporary equity to redemption value |
( |
) | ||
For the period from July 7, 2021 (inception) through December 31, 2021 |
||||||||
Class A |
Class B |
|||||||
Basic and diluted net loss per share: |
||||||||
Numerator : |
||||||||
Allocation of net loss including accretion of temporary equity |
$ |
( |
) |
$ |
( |
) | ||
Deemed dividend for accretion of temporary equity to redemption value |
— |
|||||||
Allocation of net loss |
$ |
$ |
( |
) | ||||
Denominator : |
||||||||
Weighted-average shares outstanding |
||||||||
Basic and diluted net loss per share |
$ |
$ |
( |
) |
• | in whole and not in part; |
• | at a price of $ |
• | upon not less than |
• | if, and only if, the closing price of the Class A ordinary shares equals or exceeds $ |
(Level 1) |
(Level 2) |
(Level 3) |
||||||||||
Assets |
||||||||||||
Cash and marketable securities held in trust account (1) |
$ | $ | $ |
(1) | The fair value of the marketable securities held in the Trust Account approximates the carrying amount primarily due to their short-term nature. |
Exhibit No. |
Description | |
1.1 |
||
3.1 |
||
4.1 |
||
4.2 |
||
4.3 |
||
4.4 |
||
4.5 |
||
10.1 |
||
10.2 |
||
10.3 |
||
10.4 |
||
10.5 |
||
10.6 |
||
10.7 |
||
10.8 |
||
14 | Code of Ethics. (2) | |
31.1 |
||
31.2 |
||
32.1 |
||
32.2 |
||
101.INS |
Inline XBRL Instance Document.* | |
101.SCH |
Inline XBRL Taxonomy Extension Schema Document .* | |
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document.* | |
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document.* | |
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document.* | |
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document.* | |
104 |
Cover Page Interactive Data File (Embedded as Inline XBRL document and contained in Exhibit 101).* |
* |
Filed herewith. |
** |
Furnished herewith |
(1) |
Incorporated by reference to the Company’s Registration Statement on Form S-1, filed with the SEC on November 3, 2021. |
(2) |
Incorporated by reference to the Company’s Registration Statement on Form S-1/A, filed with the SEC on November 24, 2021. |
(3) |
Incorporated by reference to the Company’s Current Report on Form 8-K, filed with the SEC on December 13, 2021. |
March 31, 2022 | INTEGRATED WELLNESS ACQUISITION CORP | |||||
By: | /s/ Steven Schapera | |||||
Name: | Steven Schapera | |||||
Title: | Chief Executive Officer (Principal Executive Officer) |
Name |
Position |
Date | ||
/s/ Steven Schapera |
Chief Executive Officer and Director | March 31, 2022 | ||
Steven Schapera | (Principal Executive Officer) |
|||
/s/ Antonio Varano Della Vergiliana |
Chairman of the Board | March 31, 2022 | ||
Antonio Varano Della Vergiliana | ||||
/s/ James MacPherson |
Chief Financial Officer and Director | March 31, 2022 | ||
James MacPherson | (Principal Financial and Accounting Officer) |
|||
/s/ Robert Quandt |
Chief Operating Officer and Director | March 31, 2022 | ||
Robert Quandt | ||||
/s/ Gael Forterre |
Director | March 31, 2022 | ||
Gael Forterre | ||||
/s/ Scott Powell |
Director | March 31, 2022 | ||
Scott Powell | ||||
/s/ Hadrien Forterre |
Director | March 31, 2022 | ||
Hadrien Forterre |